Hippocampal Atrophy on Magnetic Resonance Imaging as a Surrogate Marker for Clinical Benefit and Neurodegeneration in Early Symptomatic Alzheimer's Disease: Synthesis of Evidence from Observational and Interventional Trials.

The clinical trials for aducanumab yielded inconsistent findings: EMERGE showed significant clinical improvements on both the CDR-SB and ADAS-Cog at the highest dosage, whereas the ENGAGE active treatment arms did not reach statistical significance for either endpoint [ 43 ].

also in 111,027 other papers